Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 56.50
Bid: 55.50
Ask: 57.50
Change: 0.00 (0.00%)
Spread: 2.00 (3.604%)
Open: 56.50
High: 57.50
Low: 56.50
Prev. Close: 56.50
BSC Live PriceLast checked at -
British Smaller Companies VCT 2 is an Investment Trust

To create a portfolio that blends a mix of businesses operating in established industries with those that offer opportunities in the application and development of innovation.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

22 Nov 2016 15:30

RNS Number : 8660P
British Smaller Companies VCT2 Plc
22 November 2016
 

British Smaller Companies VCT2 plc

Interim Management Statement

For the quarter ended 30 September 2016

British Smaller Companies VCT2 plc (the "Company") presents its interim management statement for the quarter ended 30 September 2016. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

The Company has continued to make good progress in the quarter with total return rising to 112.8 pence per ordinary share. This is an increase of 1.3 pence per ordinary share; equivalent to 3.5% of the portfolio's value at 1 July 2016.

Improved profitability in a number of investments contributed to a £1.1 million return from the portfolio in the quarter, delivering a £1.2 million increase in NAV in the period (including the net income surplus of £0.1 million) prior to the payment of the interim dividend.

We have now started to see new investments being approved by HMRC and the Company has completed two new investments since the end of the quarter.

The new VCT rules have changed the nature of the businesses that the Company can invest in, with new investments needing to reinvest profits to fund their growth plans. The most recent investments have consisted mainly of equity, rather than yielding debt instruments, and this is likely to be the norm going forwards. As a result the Board would anticipate that this will reduce, in the medium term, the maintainable level of dividends compared to the 7% yield achieved historically.

Performance

 

30 September 2016

Movement

30 June 2016

Net Assets (£m)

56.8

(0.3)

57.1

NAV per share (PPS)

60.3

(0.7)

61.0

Cumulative dividends paid (PPS)

52.5

2.0

50.5

Total Return (PPS)

112.8

1.3

111.5

Shares in issue

94,152,527

682,526

93,470,001

 

The total return at 30 September 2016, calculated by reference to the NAV per ordinary share and the cumulative dividends paid per ordinary share, was 112.8 pence per ordinary share compared to 111.5 pence per ordinary share at 30 June 2016. Following payment of an interim dividend of 2.0 pence per ordinary share cumulative dividends paid have increased to 52.5 pence per ordinary share (30 June 2016: 50.5 pence per ordinary share).

The unaudited NAV per ordinary share as at 30 September 2016 was 60.3 pence per ordinary share (30 June 2016: 61.0 pence per ordinary share) representing a decrease of 0.7 pence per ordinary share. The decrease in NAV per ordinary share is due to the net upward movement in the overall portfolio valuation offset by the interim dividend paid of 2.0 pence per ordinary share.

Dividends and shares in issue

The number of ordinary shares in issue at 30 September 2016 was 94,152,527 (30 June 2016: 93,470,001). In addition, at 30 September 2016 the Company held 2,367,533 ordinary shares in treasury (30 June 2016: 2,367,533).

On 26 September 2016 the Company paid an interim dividend of 2.0 pence per ordinary share. Pursuant to its dividend re-investment scheme and on the same date the Company issued 682,526 ordinary shares at a price of 56.05 pence per ordinary share.

Much of the existing portfolio comprises investments in maturing businesses with investment structures that provide both ongoing income and repayments. The nature of the portfolio is beginning to change with the most recent investments, including those completed after the period end having to comply with the new VCT rules comprising around 8% of the invested portfolio.

Net assets

Net assets at 30 September 2016 comprised the following:

 

£000

% of net assets

Quoted investments at bid price

1,945

3.4

Unquoted investments at fair value

34,797

61.3

Total investments

36,742

64.7

Cash and cash equivalents

19,020

33.5

Other net current assets

1,035

1.8

Net assets

56,797

100.0

 

The investment portfolio at 30 September 2016 was comprised as follows:

 

Valuation

£000

Valuation as a % of net assets

Intelligent Office

3,118

5.5

ACC Aviation

2,845

5.0

Mangar Health Limited

2,493

4.4

DisplayPlan Holdings Limited

2,029

3.6

KeTech Enterprises Limited

2,000

3.5

GTK (Holdco) Limited

1,952

3.4

Business Collaborator Limited

1,727

3.0

Gill Marine Holdings Limited

1,683

3.0

Springboard Research Holdings Limited

1,646

2.9

Immunobiology Limited

1,486

2.6

 

20,979

36.9

Other investments

15,763

27.8

Total investments

36,742

64.7

During the quarter to 30 September 2016 the Company made one follow-on investment of £0.1 million into Intamac Limited.

In the quarter to 30 September 2016 the realisation and repayment of investments generated cash proceeds of £0.4 million.

Portfolio Performance

Over the quarter to 30 September 2016 aggregate unrealised portfolio valuations have increased by £1.1 million.

The Board continues to follow its policy of maintaining a diversified portfolio. At 30 September 2016, only one investment represented more than 5 per cent of the Company's NAV.

Subsequent investments

Since 30 September 2016 the Company has invested an additional £2.0 million into B2M and Traveltek.

· B2M is a leading provider of software for rugged and industrial enterprise mobile devices, based in Oxfordshire.

· Traveltek is a Scottish technology business which provides market leading dynamic technology to travel agents, tour operators and wholesalers worldwide.

 

Since HMRC issued its guidelines to the new legislation in May this year the Company has completed three new investments totalling £2.9 million. Heads of terms granting exclusivity for a further three investments totalling £3.0 million have recently been signed.

Outlook

The completion of new investments and developing pipeline of investment opportunities is encouraging. In this context the Company has decided that it will undertake a non-prospectus top-up to raise €5 million to be launched on 3 January 2017. The Board will continue to seek to further expand and diversify the portfolio recognising that its composition will change over time as the current portfolio is realised and the newer investments in younger businesses replaces it. As the return profile from these investments is likely to have a greater volatility the Board will continue to monitor its dividend and buy-back policies closely through this transition.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

 

22 November 2016

 

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Gillian Martin Nplus1 Singer Advisory LLP Tel: 0207 496 3000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
QRTZMMZMKZNGVZM
Date   Source Headline
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20247:57 amRNSIssue of Equity and Close of Offers
26th Mar 202411:10 amRNSTransaction in Own Shares and Total Voting Rights
21st Mar 20247:40 amRNSAppointment of non-executive Director
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNSAnnual Financial Report
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:26 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSIssue of Equity
18th Dec 20234:04 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
24th Nov 20237:00 amRNS3rd Quarter Results
3rd Nov 20239:40 amRNSPayment of dividend and issue of equity
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:16 amRNSTransaction in Own Shares
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
13th Sep 20237:00 amRNSHalf-year Report
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
27th Jun 20237:46 amRNSTransaction in Own Shares
26th Jun 202310:57 amRNSDirector/PDMR Shareholding
26th Jun 202310:56 amRNSPayment of Dividend and Issue of Equity
16th Jun 202312:00 pmRNS1st Quarter Results
15th Jun 20233:17 pmRNSResult of Meeting
15th Jun 20233:16 pmRNSResult of AGM
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:50 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.